Advertisement

Central European Journal of Medicine

, Volume 8, Issue 2, pp 237–243 | Cite as

Subcutaneous adipose tissue measurements and better metabolic prediction

  • Petar Ristic
  • Dubravko Bokonjic
  • Vladimir Zivkovic
  • Vladimir Jakovljevic
  • Marija Zdravkovic
  • Janko Pejovic
  • Dragana Ristic
  • Jovan Mladenovic
Research Article

Abstract

The aim of the study was to establish the importance of an additional measurement of subcutaneous adipose tissue thickness (SAT) on a predetermined position on the waistline, and its relation to waist measurements as an improvement of metabolic prediction in equally obese subjects. One hundred and forty two consecutive patients were enrolled in the study: stratified by weight as normal (body mass index — BMI 20–25 kg/m2), overweight (BMI 25–30 kg/m2) and obese (BMI >30 kg/m2); and by fasting glucose level as normoglycemic, impaired fasting glucose (IFG), or with type 2 diabetes mellitus (T2DM). SAT was measured in relaxed expiration, 3 cm left of the umbilicus, with ultrasound. Fasting blood samples for glucose, insulin and HbAlc were taken. Waist circumference was slightly higher in the IFG (112.8 cm) and normoglycemic groups (115.62 cm), compared to T2DM (108.15 cm). The T2DM group had a lower average SAT (2.7 cm) than both the IFG group (3.4 cm, p<0.01) and the normoglycemic group (4.2cm, p=0.001). The homeostatic model of assessment for insulin resistance (HOMA IR) was the lowest in normoglycemic and the highest in IFG group. Waistline radius to SAT ratio provides better insight into the deterioration of glucose metabolism than standard anthropometric markers of abdominal obesity in equally obese patients.

Keywords

Subcutaneous adipose tissue thickness Glucose metabolism deterioration Central adiposity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Kopelman P. G. Obesity as a medical problem. Nature 2000;404:635–643PubMedGoogle Scholar
  2. [2]
    Mauro M., Taylor V., Sean W., Sharma A.M. Barriers to obesity treatment European Journal of Internal Medicine 19 (2008) 173–180CrossRefGoogle Scholar
  3. [3]
    Katzmarzyk P. T., Janseen I. The economic costs associated with physical inactivity and obesity in Canada an update. Can J Appl Physiol 2004; 29:90–115PubMedCrossRefGoogle Scholar
  4. [4]
    Parnez H., Kawar B., El Nahas M. Obesity and diabetes in developing world-a growing challenge N Engl J Med 2007; 356: 213–215CrossRefGoogle Scholar
  5. [5]
    Despres J. P., Lemieux I., Bergeron J., Pibarot P., Mathieu P., Larose E., et al Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk Atheroscler Thromb Vasc Biol 2008;28: 1039–1049CrossRefGoogle Scholar
  6. [6]
    Garaulet M., Pérez-Llamas F., Pérez-Ayala M., Martínez P., de Medina F.S., Tebar F.J., et al. Site specific differences in the fatty acid composition of abdominal adipose tissue in an obese population from a Mediterran area:relation with dietary fatty acids, plasma lipid profile, serum insulin and central obesity Am J Clin Nut 2011; 74: 585–591Google Scholar
  7. [7]
    Unger R. H. Lipid overload and overflow:metabolic trauma and metabolic syndrome Trends Endocrinol Metab. 2003; 14(9):398–403PubMedCrossRefGoogle Scholar
  8. [8]
    Festa A., D Agostino R., Williams K., Mayer-Davis E.J., Tracy R.P., Haffner S.M. The relation of body fat mass and distribution to markers of chronic inflamation. Int J Obes 2001; 25:1407–1415CrossRefGoogle Scholar
  9. [9]
    Eizirik D.L., Cardozo A.K., Cnop M. The role of endoplasmatic reticulum stress in diabetes mellitus Endocr Rev. 2008; 29: 42–61PubMedCrossRefGoogle Scholar
  10. [10]
    Grill V., Björklund A. Type2 diabetes-effect of compensatory over secretion as a reason for beta cell collapse. Int Jnl experimental Diab Res 2002; 153–158Google Scholar
  11. [11]
    Yang X., Smith U. Adipose tissue distribution and risk of metabolic disease: does thiasolidinedioneinduced adipose tissue distribution provide a clue to an answer. Diabetologia 2007; 50: 1127–1139PubMedCrossRefGoogle Scholar
  12. [12]
    Stefan N., Kantartzis K., Machann J., Schick F., Thamer C., Rittig K., et al. Identification and caracterzation of metabolically benign obesity in humans. Arch intern Med 2008; 168: 1609–1616PubMedCrossRefGoogle Scholar
  13. [13]
    Hu H.H., Nayak S., Goran I.M. Assessment of abdominal adipose tissue and organ fat content by magnetic resonance imaging Obesity reviews 2011; 12: 504–515CrossRefGoogle Scholar
  14. [14]
    Muler H. P., Raudies F., Unrath A., Neumann H., Ludolph A.C., Kassubek J. Quantification of human body fat tissue percentage by MRI. NMR Biomed. 2011; 24(1):17–24CrossRefGoogle Scholar
  15. [15]
    Ozenoglu A., Ugurlu S., Can G., Sarkis C., Demirel Y. Differences in the body composition and biochemistry in women grouped as normal-weight, overweight and obese according to body mass index and their relation with cardiometabolic risk. Cent Eur J Med 2010; 5(6): 724–732CrossRefGoogle Scholar
  16. [16]
    McGee D.L. Body mass index and mortality: a meta-analysis based on person-level data from twenty-six observational studies Ann Epidemiol 2005; 15:87–97PubMedCrossRefGoogle Scholar
  17. [17]
    Ascaso J.F., Romero P., Real J.T., Lorente R.I., Martinez-Valls J., Carmena R. Abdominal Obesity, insuline resistance, and metabolic syndrome in a southern European population. European Journal of Internal Medicine 14 (2003) 101–106PubMedCrossRefGoogle Scholar
  18. [18]
    World Health Organization. Obesity: Preventing and managing the Global epidemic. Report of a WHO Consultation on obesity. World Health Organ Tech Rep Ser. 2000; 894:i–xii, 1–253Google Scholar
  19. [19]
    Lean M.E., Hans T.H., Morrison C.E. Waist circumference as a measure for indicating need for weight management Br Med J 1995;15:158–161CrossRefGoogle Scholar
  20. [20]
    Alberti K.G., Zimet P., Shaw J. The metabolic Syndrome a new worldwide definition Lancet 2005;366(9491): 1059–1062PubMedCrossRefGoogle Scholar
  21. [21]
    Gary T.C. Metabolic Syndrome or Central Obesity SindromeDiabetes Care, 2006; 29(3):752Google Scholar
  22. [22]
    Porter S.A., Majaro J.M., Hoffmann U., Vasan R.S., O Donel J., Fox C.S. Abdominal subcutaneous adipose tisue: a protective fat depot Diabetes Care. 2009 32(6):1068–1075PubMedCrossRefGoogle Scholar
  23. [23]
    Bagust A., Beale S. Deteriorating beta cell function in type 2 diabetes: a long term model Q J Med 2003; 96: 281–882CrossRefGoogle Scholar
  24. [24]
    Graber A.J., Handelsman Y., Einhorn B., Bergman D.A., Bloomgarden Z.T., Fonseca V., et al Diagnosis and menagment of prediabetes in the continium of hyperglicemia-when do the risk of diabetes begin? A consensus statement from the american college of endocrinology and the american association of clinical endocrinologists. Endocr Pract. 2008; 14(7):933–946Google Scholar
  25. [25]
    Cnop M., Clark A. The long life span and low turnover of human islet beta cells estimated by mathematical modeling of lipofuscin accumulation Diabetologia 2009; 53:321–330PubMedCrossRefGoogle Scholar
  26. [26]
    Perl S., Kushner J.A., Buchholz B.A., Meeker A.K., Stein G.M., Hsieh M. Significant human beta cell turnover is limited to the first three decades of life as determent by in vivo thymidin analog incorporation and radiocarbon dating J.Clin. End. and Metabol 2010; 95(10): 234–239CrossRefGoogle Scholar
  27. [27]
    Brown R.J., Rother K.I. Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data. Pediatric Diabetes 2008; 9(part II):14–22PubMedCrossRefGoogle Scholar
  28. [28]
    XU Wen, LI Yan-bing, DENG Wan-ping, HAO Yuan-tao and WENG Jian-ping Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long term follow up study Chin Med J 2009; 122(21); 2554–2559.PubMedGoogle Scholar
  29. [29]
    Li Y., Xu W., Liao Z., Yao B., Chen X., Huang Z., et al. Induction of long term glicemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta cell function; Diabetes Care 2004; 27:2597–2502PubMedCrossRefGoogle Scholar
  30. [30]
    Weng J., Li Y., Xu W., Shi L, Zhang Q., Zhu D., et al. Effect of intensive insulin therapy on beta cell function and glycemic control in patients with newly diagnosed type 2 diabetes: a multicenter randomized parallel-group trial. Lancet 2008; 371: 1753–1760PubMedCrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Petar Ristic
    • 1
  • Dubravko Bokonjic
    • 2
  • Vladimir Zivkovic
    • 3
  • Vladimir Jakovljevic
    • 3
  • Marija Zdravkovic
    • 4
  • Janko Pejovic
    • 5
  • Dragana Ristic
    • 6
  • Jovan Mladenovic
    • 7
  1. 1.Endocrinology ClinicMilitary Medical AcademyBelgradeSerbia
  2. 2.Centre for Poisoning ControlMilitary Medical AcademyBelgradeSerbia
  3. 3.Department of Physiology, Faculty of MedicineUniversity of KragujevacKragujevacSerbia
  4. 4.Department of CardiologyUniversity Hospital Medical Center “Bezanijska kosa”, Faculty of Medicine, University of BelgradeBelgradeSerbia
  5. 5.Dept. of BiochemistryMilitary Medical AcademyBelgradeSerbia
  6. 6.Eye ClinicMilitary Medical AcademyBelgradeSerbia
  7. 7.Institute of EpidemiologyMilitary Medical AcademyBelgradeSerbia

Personalised recommendations